Current Report Filing (8-k)
June 12 2019 - 5:28PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 6, 2019
Medicine
Man Technologies, Inc.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
001-36868
|
|
46-5289499
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
IRS Employer
Identification No.)
|
4880 Havana Street, Suite 201
Denver, Colorado
|
|
80239
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(303) 371-0387
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered
pursuant to Section 12(b) of the Act: none
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01 Entry into a Material Definitive Agreement.
On June 6, 2019 (the “Execution
Date”), Medicine Man Technologies (the “Company”), a Nevada corporation, entered into a binding term sheet (the
“Term Sheet”) with the stockholders (the “Sellers”) of Green Equity S.A.S. (“Green Equity”),
a Republic of Colombia simplified stock corporation, setting forth the terms of the acquisition by the Company of 100% of the
capital stock and assets of Green Equity (the “Acquisition”). Green Equity, a company based in Bogota, Columbia, holds
all four licenses in Columbia allowing it to grow, process, retail and export.
The terms of the Term Sheet are summarized
as follows:
As consideration, the Company shall pay
a total purchase price of $5,400,000 (the “Purchase Price”) consisting of $450,000 cash and 1,292,428 shares of its
common stock, par value $0.001 per share. The 1,292,428 shares was determined by using the closing price of Company’s common
stock on the day prior to the Execution Date, which equated to $3.83 per share.
The Term Sheet contemplates the parties
entering into a share purchase agreement to effectuate the Acquisition. The obligations of the parties to close on the Acquisition
are conditioned upon the satisfaction of certain conditions, including but not limited to:
|
i.
|
the absence of any governmental or judicial orders that prevent the Sellers from transferring their
shares
|
|
i.
|
Green Equity amending a certain lease agreement to extend the lease term for at least an additional
two years;
|
|
ii.
|
receipt of the requisite approvals to consummate the transaction
|
|
ii.
|
waiver of their right of first set forth in the bylaws of Green Equity; and
|
|
iii.
|
satisfactory completion of due diligence by the Company.
|
On June 12, 2019, the Company issued a
press release with respect to the foregoing, a copy of which is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and
Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
Medicine Man Technologies, Inc.
|
|
|
|
Date: June 12, 2019
|
By:
|
/s/
Andrew Williams
|
|
Name:
|
Andrew Williams
|
|
Title:
|
Chief Executive Officer
|
Medicine Man Technologies (CE) (USOTC:SHWZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medicine Man Technologies (CE) (USOTC:SHWZ)
Historical Stock Chart
From Jul 2023 to Jul 2024